Danish pharma group Novo Nordisk has revealed it is in exclusive negotiations that could result in the acquisition of a controlling stake in Biocorp, a French company that makes medical devices ...

We recently published a list of 10 Best Beaten Down Stocks to Buy According to Analysts. In this article, we are going to ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

The two main ingredients in this drug cannot be dissolved together, so it must be administered by an injection device with two chambers. Novo Nordisk’s manufacturing capacity for CagriSema is ...

President Trump has announced sweeping tariffs on several countries. Novo Nordisk and Smith & Nephew may be the most at risk ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Artisan Global Opportunities Fund stated the following regarding Novo Nordisk A/S (NYSE:NVO) in its Q4 2024 investor letter: "Among our top detractors were Advanced Micro Devices (AMD), Novo ...

Novo Nordisk (NVO) stock was down more than 8% Monday ... difficult to manufacture than tirzepatide due to its dual-chamber device, and NVO's future manufacturing capacity is TBD," wrote Leerink ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) built its business on insulin and has emerged as a leading innovator in GLP-1 agonists, relatively new drugs that treat obesity and type 2 diabetes by ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...